Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PHGDH | O43175 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1824971 | 0.97 | SMN1; SMN2 (0.52) | SMN1; SMN2L3MBTL3L3MBTL1HRH3OPRL1 | |
| SCHEMBL35550 | 0.97 | SMN1; SMN2 (0.52) | SMN1; SMN2L3MBTL3L3MBTL1HRH3OPRL1 | |
| SCHEMBL5709151 | 0.97 | SMN1; SMN2 (0.52) | SMN1; SMN2L3MBTL3L3MBTL1HRH3OPRL1 | |
| SCHEMBL9425142 | 0.94 | SMN1; SMN2 (0.54) | SMN1; SMN2L3MBTL3L3MBTL1HRH3OPRL1 | |
| SCHEMBL26025479 | 0.93 | SMN1; SMN2 (0.48) | SMN1; SMN2L3MBTL3L3MBTL1HRH3OPRL1 | |
| Methylamine SCHEMBL28019730 | 0.91 | SMN1; SMN2 (0.47) | SMN1; SMN2L3MBTL3L3MBTL1HRH3OPRL1 | |
| SCHEMBL14907095 | 0.91 | L3MBTL3 (0.49) | SMN1; SMN2L3MBTL3L3MBTL1HRH3ALDH1A1 | |
| SCHEMBL25672747 | 0.89 | L3MBTL3 (0.47) | SMN1; SMN2L3MBTL3L3MBTL1HRH3ALDH1A1 | |
| SCHEMBL3168997 | 0.88 | — | — | |
| SCHEMBL26112782 | 0.88 | SMN1; SMN2 (0.52) | SMN1; SMN2L3MBTL3L3MBTL1HRH3OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115784474-A | High-temperature-resistant high-pressure-resistant phosphorus-free sodium-free or low-sodium scale and corrosion inhibitor for boiler and preparation method and application thereof | 上海聚焓能源科技有限公司 | 2023-03-14 | — | — | CN | claimed |
| CN-111517922-B | Method for preparing 4-chloro-3,5-dimethylphenol | 万华化学集团股份有限公司 | 2022-11-04 | — | — | CN | claimed |
| CN-111517922-A | Method for preparing 4-chloro-3, 5-dimethylphenol | 万华化学集团股份有限公司 | 2020-08-11 | — | — | CN | claimed |
| EP-2897970-B1 | MACROLIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2016-07-13 | — | — | EP | claimed |
| US-20150210729-A1 | MACROLIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2015-07-30 | — | — | US | claimed |
| EP-2897970-A1 | MACROLIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2015-07-29 | — | — | EP | claimed |
| WO-2014044645-A1 | MACROLIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2014-03-27 | — | — | WO | claimed |
| EP-4594309-A1 | AZOLE MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | Genentech Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| WO-2024073662-A1 | AZOLE MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | GENENTECH, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| US-11738487-B2 | Processes for making molded flexible foams and flexible foams produced thereby | COVESTRO LLC (US) | 2023-08-29 | — | — | US | disclosed |
| CN-115784474-A | High-temperature-resistant high-pressure-resistant phosphorus-free sodium-free or low-sodium scale and corrosion inhibitor for boiler and preparation method and application thereof | 上海聚焓能源科技有限公司 | 2023-03-14 | — | — | CN | disclosed |
| CN-111517922-B | Method for preparing 4-chloro-3,5-dimethylphenol | 万华化学集团股份有限公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-114805727-A | Process for preparing molded flexible foams and flexible foams prepared therefrom | 科思创有限公司 | 2022-07-29 | — | — | CN | disclosed |
| EP-0268975-A2 | Process for the preparation of mono, bi and tricyclic amino acids, intermediary compounds and their preparation | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-06-01 | — | — | EP | disclosed |
| US-4666461-A | Fuel treatment compositions | THE LUBRIZOL CORPORATION (US) | 1987-05-19 | — | — | US | disclosed |
| EP-0085510-B1 | COMPOSITIONS FOR USE IN ALCOHOL AND ALCOHOL CONTAINING FUELS | The Lubrizol Corporation (US) | 1986-04-16 | — | — | EP | disclosed |
| US-4442286-A | Preparation of amines by the reduction of imines with phosphorous acid | PETROLITE CORPORATION (US) | 1984-04-10 | — | — | US | disclosed |
| EP-0085510-A2 | Compositions for use in alcohol and alcohol containing fuels | The Lubrizol Corporation (US) | 1983-08-10 | — | — | EP | disclosed |
| US-4384968-A | TREATING GAS STREAM WITH MORPHOLINE OR SERIVATIVE | BETZ LABORATORIES, INC. (US) | 1983-05-24 | — | — | US | disclosed |
| US-3979380-A | INOTROPIC ACTIVITY, CARDIAC STIMULANTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1976-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210729-A1 | MACROLIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | PCSK9, CYP51A1, ABCB11 | SMN1; SMN2 1981/4885L3MBTL3 4769/4885L3MBTL1 4638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.